OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT

News

4/25/2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

 
Nearly $12 million in cash and investment
 
Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders
 
Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation

Read More

4/12/2022

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

 

Read More

    Archives

    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

    Categories

    All

    RSS Feed

Psychedelic Pharmaceuticals

COMPANY  /  RESEARCH  /  INVESTORS  /  NEWS  /  CONTACT


Publicly-traded on the OTCQB: PHRRF and CSE: PHRM
© COPYRIGHT 2022.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.